Envista (NYSE:NVST) Releases FY 2026 Earnings Guidance

Envista (NYSE:NVST) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.500-1.550 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

NVST has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler boosted their price target on Envista from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Evercore reissued an “outperform” rating and set a $33.00 price target on shares of Envista in a research note on Thursday, May 7th. Morgan Stanley increased their price target on Envista from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Friday, April 24th. Finally, Weiss Ratings downgraded Envista from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Six research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.62.

Envista Trading Up 2.0%

Shares of NVST stock traded up $0.55 during trading hours on Wednesday, hitting $28.51. 6,998,014 shares of the company were exchanged, compared to its average volume of 2,953,375. The firm has a market cap of $4.64 billion, a PE ratio of 69.54, a PEG ratio of 1.55 and a beta of 0.86. Envista has a 1 year low of $18.77 and a 1 year high of $30.42. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The firm has a fifty day moving average of $25.76 and a 200 day moving average of $25.96.

Envista (NYSE:NVST) last released its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07. Envista had a net margin of 2.41% and a return on equity of 7.11%. The business had revenue of $730.50 million for the quarter, compared to analysts’ expectations of $716.11 million. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Analysts expect that Envista will post 1.42 earnings per share for the current year.

Institutional Trading of Envista

Several institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC increased its holdings in shares of Envista by 13.1% during the 4th quarter. Parallel Advisors LLC now owns 3,175 shares of the company’s stock worth $69,000 after buying an additional 367 shares during the last quarter. Bank of Montreal Can boosted its holdings in Envista by 1.4% in the fourth quarter. Bank of Montreal Can now owns 26,178 shares of the company’s stock valued at $568,000 after acquiring an additional 372 shares during the last quarter. Sepio Capital LP grew its position in Envista by 1.2% during the fourth quarter. Sepio Capital LP now owns 31,632 shares of the company’s stock valued at $687,000 after acquiring an additional 374 shares during the period. Deutsche Bank AG grew its position in Envista by 2.9% during the fourth quarter. Deutsche Bank AG now owns 17,412 shares of the company’s stock valued at $378,000 after acquiring an additional 484 shares during the period. Finally, UMB Bank n.a. increased its stake in Envista by 46.1% during the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock worth $44,000 after acquiring an additional 636 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.